Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference
December 02, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Third Quarter Ended September 30, 2019
November 05, 2019 16:02 ET
|
Aptose Biosciences, Inc.
CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical Response Conference Call...
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019
October 22, 2019 07:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...
Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)
October 10, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies
September 16, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Reports Results for the Second Quarter Ended June 30, 2019
August 06, 2019 16:00 ET
|
Aptose Biosciences, Inc.
─ APTO-253 Inhibits MYC in AML and MDS Patients in Phase 1 Clinical Trial ─ ─ First CLL Patient Dosed with CG-806 in Phase 1 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today ...
Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference
July 30, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019
July 23, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
July 16, 2019 07:05 ET
|
Aptose Biosciences, Inc.
– CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – APTO-253 MYC inhibitor being developed for the...
Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
June 14, 2019 07:00 ET
|
Aptose Biosciences, Inc.
– CG-806 safely and durably suppressed tumor growth in preclinical models – SAN DIEGO and TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:...